LATEST NEWS
NeuroDelta presents at EPIC Biotechnology Conference... More here

OVERVIEW

NeuroDelta Limited is a biotechnology company, established in May 2003 to identify and commercialise novel therapeutic and diagnostic targets for Alzheimer's Disease (AD). Alzheimer's Disease is an enormous problem, representing the most common form of dementia amongst older people and is marked by a gradual, irreversible loss of cognitive ability.

• There are 8-10 million sufferers in the World's 7 major pharmaceutical markets

• Over the next 30-40 years the number of patients with AD will triple

• Currently, the disease costs $100 billion annually in the U.S. alone, including $92 billion in lost productivity of caregivers and direct health costs estimated at $8 billion, with about $575 million in drug costs

• Existing therapies have limited impact, giving no more than a 4% savings in the average care costs

With a strong IP position, NeuroDelta is the leading company for development of agents to treat disorders associated with phosphorylated amyloid-β.